SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?

To: margie who wrote (3964)3/26/1998 1:27:00 AM
From: Joe E.  Read Replies (2) | Respond to of 6136
 
Here is news on a three drug cocktail with protease inhibitors:
dailynews.yahoo.com

From this story it does not appear that this combination is as effective as the current best treatment, which includes protease inhibitors.



To: margie who wrote (3964)3/27/1998 1:30:00 PM
From: JR  Read Replies (1) | Respond to of 6136
 
Thanks for your response to the Zacks question. Any thoughts on why Agouron's stock has been relatively quiet lately, especially in light of the stable market share data for the last couple of months and the European and Japanese approvals? Is the market holding its breath for eps report and conference presentations?


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News